As of Feb 23
| -0.03 / -0.43%|
The 1 analysts offering 12-month price forecasts for Clinuvel Pharmaceuticals Ltd have a median target of 25.66, with a high estimate of 25.66 and a low estimate of 25.66. The median estimate represents a +273.46% increase from the last price of 6.87.
The current consensus among 1 polled investment analysts is to Buy stock in Clinuvel Pharmaceuticals Ltd. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.